Presentations and Publications
01/25/2025
Vilastobart Poster Presentation at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium
Phase 1/2 Study of Vilastobart (XTX101), a Tumor-Activated, Fc-enhanced Anti-CTLA-4 Monoclonal Antibody, in Combination with Atezolizumab in Patients with Advanced Solid Tumors and in MSS CRC
11/07/2024
Vilastobart Poster Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Phase 1/2 Study of Vilastobart (formerly XTX101), a Tumor-Activated, Fc-enhanced Anti-CTLA-4 Monoclonal Antibody, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
11/07/2024
Tumor Activated Cell Engager Poster Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models
06/01/2024
XTX202 Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Phase 1/2 Study of XTX202, a Tumor-Activated IL-2βγ in Advanced Solid Tumors
More XILIO News
04/07/2024
XTX501, a tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models
12/12/2023
XTX101 Publication in Journal for ImmunoTherapy of Cancer
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
12/07/2023
XTX101 Poster Presentation at the 2023 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Phase 1/2 Study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
11/30/2023
XTX301 Publication in Molecular Cancer Therapeutics
XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies
11/04/2023
XTX301 Poster Presentation at the 2023 Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
XTX301, a tumor-activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models
11/03/2023
XTX202 Poster Presentation at the 2023 Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
XTX202-01, Phase 1/2 first-in-human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors
06/30/2023
XTX301 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12) in patients with advanced solid tumors
04/16/2023
XTX301 Poster Presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting
A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models
04/16/2023
PD1/IL-2 Multifunctional Poster Presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Tumor-activated PD1-directed IL-2 increased antigen specific T cells in tumors and demonstrated anti-tumor activity in mice
11/10/2022
XTX202 Poster Presentation at the 2022 Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice
06/05/2022
XTX202 Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202, a Tumor-Selective Interleukin-2 (IL-2), in Patients with Advanced Solid Tumors
05/10/2022
XTX301 Poster Presentation at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2022 Conference
A half-life extended, tumor selective IL-12 activated tumor infiltrating immune cells and demonstrated anti-tumor activity in the MC38 syngeneic mouse model
11/12/2021
XTX301 Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
XTX301, A Protein-engineered IL-12, Exhibits Tumor-selective Activity In Mice Without Peripheral Toxicities And Is Well Tolerated In Non-Human Primates
11/12/2021
XTX101 (CTLA-4) Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors
10/17/2021
Poster Presentation at the 9th Annual Meeting of the International Cytokine and Interferon Society (ICIS)
Engineering Geographically Precise Activation of Cytokines To Achieve Improved Therapeutic Benefit in Oncology and Beyond
09/22/2021
Presentation at the Next-Gen Cytokine Therapeutics Summit
Tumor selective cytokines for cancer therapy
06/08/2021
XTX202 (IL-2) Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
XTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
05/12/2021
XTX101 (CTLA-4) Poster Presentation at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 Virtual Symposium
Tumor-Activated Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Monotherapy and Anti-PD-1 Combination Benefit in Preclinical Models
11/13/2020
XTX101 (CTLA-4) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
Tumor-activated Fc-engineered Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Tumor-selective PD and Efficacy in Preclinical Models
11/12/2020
XTX201 (IL-2) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates